文献速递消化系统肿瘤

欧洲结直肠癌筛查对癌症特异性死亡率的影响:系统综述

Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review.
PubMed 文献 · Eur J Cancer · 2020-01-10

该系统综述检索截至2018年3月的多个数据库,纳入18项研究,评估欧洲地区不同结直肠癌筛查方法对死亡率的影响。结果显示,受邀筛查人群中,gFOBT使结直肠癌死亡率降低8%至16%,FS降低21%至30%,且不同欧洲地区效果相似。

要点

  • gFOBT筛查可降低结直肠癌死亡率8%至16%,FS降低21%至30%。
  • 不同欧洲地区采用相似筛查策略的死亡率效果可能一致。
  • 纳入研究包括8项随机临床试验和10项观察性研究。

核心结论

  • 采用相似筛查策略(gFOBT或FS)邀请个体筛查,其结直肠癌死亡率影响在欧洲多个地区可能一致。

研究设计与样本

  • 系统综述,检索Embase、Medline、Web of Science、PubMed publisher、Google Scholar和Cochrane Library截至2018年3月的文献。
  • 共纳入18项研究,其中11项关于gFOBT,4项关于FS,2项关于FIT,1项关于结肠镜;8项为随机临床试验,10项为观察性研究。

主要发现

  • 受邀筛查人群中,gFOBT的结直肠癌死亡率降低范围为8%至16%。
  • 受邀筛查人群中,FS的结直肠癌死亡率降低范围为21%至30%。
  • 当纳入高偏倚风险研究时,范围更广。
  • gFOBT和FS筛查的估计效果在不同欧洲地区似乎相似。

临床怎么用

  • 在欧洲人群中,采用gFOBT或FS邀请筛查可预期降低结直肠癌死亡率,且效果在不同地区可能一致。

局限性

  • 纳入研究包括高偏倚风险研究,可能导致效果估计范围更广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Populations differ with respect to their cancer risk and screening preferences, which may influence the performance of colorectal cancer (CRC) screening programs. This review aims to systematically compare the mortality effect of CRC screening across European regions. METHODS: Six databases including Embase, Medline, Web of Science, PubMed publisher, Google Scholar and Cochrane Library were searched for relevant studies published before March 2018. Bibliographic searches were conducted to select studies assessing the effect of various screening tests (guaiac fecal occult blood test [gFOBT]; flexible sigmoidoscopy [FS]; fecal immunochemical test [FIT] and colonoscopy) on CRC mortality in Europe (PROSPERO protocol: CRD42016042433). Abstract reviewing, data extraction and risk of bias assessment were conducted independently by two reviewers. RESULTS: A total of 18 studies were included; of which, 11 were related to gFOBT, 4 to FS, 2 to FIT and 1 to colonoscopy; 8 were randomised clinical trials, and 10, observational studies, and an approximately equal number of studies represented Northern, Western and Southern European regions. Among individuals invited to screening, CRC mortality reductions varied from 8% to 16% for gFOBT and from 21% to 30% for FS. When studies with a high risk of bias were considered, ranges were more extensive. The estimated effectiveness of gFOBT and FS screening appeared similar across different European regions. CONCLUSIONS: CRC mortality impact of inviting individuals with similar adopted screening strategies (gFOBT or FS) may be consistent across several European settings.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gini A, Jansen EEL, Zielonke N, et al. Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. Eur J Cancer. 2020. PMID: 31932176. doi:10.1016/j.ejca.2019.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。